Home » Stocks » Inspyr Therapeutics

Inspyr Therapeutics, Inc. (NSPX)

Stock Price: $0.0200 USD -0.0050 (-19.68%)
Updated Oct 20, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.40M
Revenue (ttm) n/a
Net Income (ttm) -1.92M
Shares Out 120.07M
EPS (ttm) -1.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $0.0200
Previous Close $0.0249
Change ($) -0.0050
Change (%) -19.68%
Day's Open 0.0264
Day's Range 0.0197 - 0.0270
Day's Volume 8,060,117
52-Week Range 0.0005 - 0.14

More Stats

Market Cap 2.40M
Enterprise Value 4.89M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 120.07M
Float 120.07M
EPS (basic) -0.29
EPS (diluted) -1.04
FCF / Share -0.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta -15.84
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -487,000
Net Income -1.92M
Free Cash Flow -368,000
Net Cash -2.49M
Net Cash / Share -0.02
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -164.08%
ROE n/a
ROIC 20.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$637.50*
Low
638
Current: $0.0200
High
638
Target: 637.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-0.61-0.72-5.85-3.19-6.07-7.00-6.40-6.88-6.32-4.17
Net Income-0.93-0.01-11.10-3.19-5.89-6.99-5.30-6.92-5.71-4.26
Shares Outstanding0.230.030.160.050.040.030.030.020.020.02
Earnings Per Share-4.20-6.60-82.21-91.21-149.72-207.02-189.04-288.06-243.05-225.05
Operating Cash Flow-0.31-0.20-1.09-2.73-4.63-5.04-4.71-4.52-3.74-2.77
Capital Expenditures-------0.01-0.01--
Free Cash Flow-0.31-0.20-1.10-2.73-4.64-5.05-4.72-4.53-3.74-2.77
Cash & Equivalents0.020.330.010.552.472.323.592.355.533.67
Total Debt2.832.602.48--0.110.110.110.110.11
Net Cash / Debt-2.80-2.27-2.470.552.472.213.482.245.433.57
Assets0.020.370.070.732.682.633.892.575.693.86
Liabilities8.758.638.921.624.592.532.633.302.642.57
Book Value-8.72-8.27-8.85-0.89-1.910.101.26-0.733.051.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Inspyr Therapeutics, Inc.
Country United States
Employees 1
CEO Michael Cain

Stock Information

Ticker Symbol NSPX
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: NSPX

Description

Inspyr Therapeutics, clinical-stage pharmaceutical company, focuses on the development of therapeutics for the treatment of diseases. It focuses on a pipeline of small molecule adenosine receptor modulators, such as A2B antagonists, dual A2A/A2B antagonists, and A2A agonists. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.